Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia

Abstract

Dear Editor, Dasatinib (DAS) is an oral dual Abl and Src tyrosine kinase inhibitor licensed in the treatment of chronic myeloid leukemia (CML) [1, 2] and is well known to exert an immunomodulatory effect both in vivo and in vitro [3]. DAS shows a distinct toxicity profile among which a previously unrecognized adverse event (AE) is represented by persistent… (More)
DOI: 10.1007/s00277-017-3105-8

Topics

1 Figure or Table

Slides referencing similar topics